Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Concurrent chemoradiotherapy (CRT) is the backbone of curative treatment for locally advanced cervical cancer, and PD-(L)1 blockade has entered first-line practice. Yet the pivotal trials diverge: pembrolizumab added to CRT improved survival in KEYNOTE-A18, whereas durvalumab did not in CALLA. Most prior syntheses organize the cervical tumor immune microenvironment by cell type and rely on cross-sectional, pre-treatment sampling, and several predate KEYNOTE-A18 and recent longitudinal multi-omic data. Here we reframe the question along the treatment time axis. Section 1.1 reports that evidence base in full, under tiered eligibility criteria. Drawing on the still-small body of studies with paired or serial pre-, on-, and post-treatment sampling of tumor and blood, we reconstruct four sequential states: an HPV-shaped baseline ecology; an early immunogenic priming window driven by DNA-damage sensing and type I interferon; a mid-treatment window in which intratumoral activation coexists with radiation-induced lymphodepletion and compensatory checkpoint upregulation; and a post-treatment state of viral-antigen persistence, minimal residual disease, and adaptive resistance. We use this lens to interpret CRT–immune checkpoint inhibitor (ICI) trial heterogeneity without over-attributing it, and derive a falsifiable prediction, which neither pivotal trial can adjudicate and which the best available randomized-evidence synthesis currently opposes: blockade delivered within the priming window may outperform equal exposure given as post-CRT maintenance, in patients who mount on-treatment activation without catastrophic lymphodepletion. This is a mechanistically motivated hypothesis, not an inference from existing results. Testing needs a factorial or biomarker-stratified trial. We also propose a temporal biomarker framework spanning baseline-predictive, on-treatment early-response, and post-treatment residual-disease markers, graded by evidence and offered as a research agenda. For each stage we name the design that would qualify or refute it. Stage 1 needs registered analysis of archival trial tissue. Stage 2 needs a nested correlative sub-study with prespecified effect modifiers. Stage 3 needs a blinded, prespecified prognostic cohort. We propose, as a hypothesis for prospective testing, that response to CRT–ICI may depend less on any single baseline feature than on whether a patient completes the dynamic transition from viral-antigen exposure through antigen presentation and T-cell recruitment to durable surveillance.